enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Anti-amyloid drugs - Wikipedia

   en.wikipedia.org/wiki/Anti-amyloid_drugs

   Aducanumab, sold under the brand name Aduhelm, is an anti-amyloid drug designed to treat Alzheimer's disease. It is a monoclonal antibody that targets aggregated forms (plaque) of amyloid beta (Aβ) found in the brains of people with Alzheimer's disease to reduce its buildup. [10] It was developed by Biogen and Eisai. [11] Aducanumab is given via intravenous infusion. [5] Aducanumab was ...

3. New drug's potentially fatal side effects obscured by ... - AOL

   www.aol.com/news/drugs-potentially-fatal-side...

   The FDA had proposed that companies testing new anti-amyloid drugs exclude any volunteer from clinical trials who had more than two brain microbleeds, according to an Alzheimer's Assn. report.

4. New test may tell who is prone to side effects from Alzheimer ...

   www.aol.com/test-may-tell-prone-side-153000197.html

   The Food and Drug Administration (FDA) approved lecanemab, sold under the brand name Leqembi — the first anti-amyloid medication for the treatment of Alzheimer’s disease.

5. U.S. approves Alzheimer's drug that modestly slows disease - AOL

   www.aol.com/news/alzheimers-drug-modestly-slows...

   This Dec. 21, 2022 image provided by Eisai in January 2023, shows vials and packaging for their medication Leqembi. On Friday, Jan. 6, 2023, U.S. health officials approved Leqembi, a new Alzheimer ...

6. Aducanumab - Wikipedia

   en.wikipedia.org/wiki/Aducanumab

   Aducanumab, sold under the brand name Aduhelm, is an anti-amyloid drug designed to treat Alzheimer's disease. [2] [3] It is a monoclonal antibody [3] [2] that targets aggregated forms (plaque) [4] [5] of amyloid beta (Aβ) found in the brains of people with Alzheimer's disease to reduce its buildup.

7. Donanemab - Wikipedia

   en.wikipedia.org/wiki/Donanemab

   The US Food and Drug Administration (FDA) label for donanemab contains a boxed warning about amyloid-related imaging abnormalities. [1]Side effects may include infusion-related reactions, with symptoms such as flu-like symptoms, nausea, vomiting and changes in blood pressure, and hypersensitivity reactions, including anaphylaxis (severe, life-threatening allergic reaction) and angioedema ...

8. How a new FDA-approved drug can — and can’t — help people ...

   www.aol.com/fda-approved-drug-t-help-121600044.html

   In early 2023, the U.S. Food and Drug Administration (FDA) granted accelerated approval to a new Alzheimer’s drug called Leqembi. (Biogen, a biotechnology company, and Eisai, a pharmaceutical ...

9. Lecanemab - Wikipedia

   en.wikipedia.org/wiki/Lecanemab

   Lecanemab may cause amyloid-related imaging abnormalities (ARIA). ARIA is often asymptomatic, but serious and life-threatening events rarely may occur.ARIA most commonly presents as temporary swelling of the brain that usually resolves over time and may be accompanied by small spots of bleeding in or on the surface of the brain, though some people may have symptoms such as headache, confusion ...